Current Report Filing (8-k)
June 10 2019 - 12:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 10, 2019
OBALON THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
|
|
|
|
001-37897
|
|
20-1828101
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
5421 Avenida Encinas, Suite F
Carlsbad, California
|
|
92008
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(844) 362-2566
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per share
|
OBLN
|
The NASDAQ Stock Market LLC
(NASDAQ Global Market)
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Item 8.01 Other Events.
On June 10, 2019, Obalon Therapeutics, Inc. (the “Company”) issued a press release announcing the appointment of Bob MacDonald to the newly created position of Chief Retail Officer. The Company also noted that, as part of its revised commercial strategy, it has offered voluntary separation packages to approximately 15 employees, including several senior executives. A copy of the press release containing these announcements is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
OBALON THERAPEUTICS, INC.
|
|
|
|
Date: June 10, 2019
|
|
By:
|
/s/ William Plovanic
|
|
|
|
William Plovanic
|
|
|
|
President and Chief Financial Officer
|
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Sep 2023 to Sep 2024